Longevity & AgingNewLimit Is Using Epigenetic Reprogramming to Turn Back the Clock on Human Cells
NewLimit is a biotech company targeting the root biology of aging by reprogramming cells to behave younger. Rather than fully reverting cells to a stem-cell state — which risks cancer — they use partial reprogramming to restore youthful gene expression patterns. Their platform screens thousands of transcription factors using AI and machine learning to find combinations that rejuvenate cells. Instead of traditional gene therapy, they deliver these factors via mRNA packaged in lipid nanoparticles, a safer and more controllable approach. The company is currently working through preclinical models, including humanized mouse models, before advancing toward human clinical trials. This interview with Head of Operations Cathy O'Hare breaks down the science, the platform, and the roadmap for turning cellular rejuvenation into real therapies.
